Situated in the Sino-Singapore Guangzhou Knowledge City in Luogang, Huangpu District, Guangzhou Huacheng Pharmaceutical Factory (HCPF) is a pharmaceutical company with time-honored brand status and a history of over 40 years. The premises cover an area of 134 thousand square meters, and the firm is regarded as a key enterprise in Guangzhou’s TCM modernization.

HCPF began as Guangzhou Hongwei Pharmaceutical Factory established in March, 1971. After over 40 years’ development, HCPF has expanded into a company with more than 580 existing staff members and over 140 scientific and technical personnel, featuring more than 150 products of national standard and eight dosage forms including tablets, instant granules, pills, capsules, oral solutions, mixtures, syrup and soft extracts.

The firm mainly produces Houerhuan Xiaoyan Pian (for diminishing inflammation), Fufang Ganmaoling Pian (for relieving cold), Zhongganmaoling Pian (for relieving severe cold and flu), Banlangen Keli (for heat clearing and detox) and Cefalexin Capsules. In particular, its Houerhuan Xiaoyan Pian, Qutan Zhike Keli (for eliminating phlegm and relieving cough), Yiqi Wenyang Jiaonang (for promoting blood circulation to remove meridian obstruction) and Tianlong Xifeng Keli (for calming the liver and relieving dizziness) are market exclusive products.

HCPF is a modern state-owned Chinese and western patent medicine manufacturer over the past 40 years focusing on technology research, design, production, sales and service. The newly established TCM solid preparation GMP workshop, instant granule GMP workshop, reformed TCM liquid preparation workshop and western medicine preparation workshop adopt recently introduced massive modern medical devices like electronic monitoring codes and automatic packaging lines that comply with GMP’s new requirements, carrying out the overall monitoring and management of the production of drugs.

The quality management department has been equipped with advanced sophisticated testing instruments such as ultraviolet and visible light spectrophotometers, atomic absorption spectrophotometers, fourier transformation infrared spectrometers, gas chromatographs, a thin layer chromatogram scanner and automatic high performance liquid chromatograph.

The research and development department has a competent technological team specializing in the research and development of new products. Based on market requirements, the team worked with higher education institutions and key research institutions to develop new products and increase corporate competency.

Every year, HCPF recruit new blood from key medical colleges and universities across the whole of China and assign technological staff members to go abroad for further study so as to strengthen the  company’s technological know-how.

HCPF also maintains a good relationship with various technological institutions such as the China State Institute of Pharmaceutical Industry, the China Academy of Chinese Medical Sciences, the Chinese Center for Disease Control and Prevention, the Institute of Integration of Traditional Chinese and Western Medicine affiliated with Hunan Medical University (now merged into Central South University) and Tianjin Institute of Pharmaceutical Research.

During the 11th Five-year Plan, the company worked on a nationally-approved program with Chinese PLA General Hospital and HFUT Hefei University of Technology to develop Ginkgolide B Injection using the innovative model of industry-university cooperation. The program has been acclaimed as one of the most renowned Pharmaceutical Projects of Guangdong TCM Development during the 11th Five-year Plan.    

HCPF implements the strategy of ‘One Focus and Multiple Offshoots’, cultivating new economic growth points for the company. Over the recent years, it has maintained strong development momentum with increasingly strong economic performance and market shares. It has achieved an annual industrial output of more than 350 million RMB and profits and tax revenues of over 20 million RMB, making a powerful contribution to the country’s development.

Being approved by the newest GMP standards is the essential criterion for a pharmaceutical company to increase comprehensive competency and participate competitively in the marketplace. In 2012, with the support of GPHL, HCPF invested 58 million RMB to make sure its eight dosage forms approved by the GMP of China Food and Drug Administration and Guangdong Food and Drug Administration for three consecutive years since 2003, laying a solid foundation for the leapfrog development of the company.

GMP’s approval will definitely usher in a new look HCPF. Under the guidance of Grand Southern TCM, Grand Commerce and Grand Health Care put forward by GPHL, HCPF has proposed a plan of ‘1129 Programs’ aiming to build up a modern enterprise with advanced technology, scientific management, top-notch equipment and quality products and services.

(Translator: Cheryl Ma; Editors: Simon Haywood, Olivia Yang, Monica Liu)